Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Pancreatic Neoplasms 8Neoplasms 5Non-Muscle Invasive Bladder Neoplasms 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Uterine Cervical Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Platinum-resistant Ovarian Cancer 1Pharmacokinetics 1Multiple Myeloma 1Microsatellite Instability 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1

Interventions

Imatinib Mesylate 2Cetuximab 2spartalizumab 1pembrolizumab 1avelumab 1Radiotherapy 1Radiation 1Cyclophosphamide 1Bacterial Load 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Chordoma × ALT-803 × Clear all
NCT03647423 2025-02-21

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Sarcoma

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡